fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Green light for 16 new medicines in the EU

Written by | 22 May 2025

April was a bumper month for drug approvals in Europe, with sixteen new products recommended by the European Medicines Agency’s (EMA) key committee on human medicines. This almost… read more.

Tepezza (teprotumumab-trbw) receives approval in Japan for the treatment of active thyroid eye disease – Amgen

Written by | 5 Oct 2024

Amgen announced  Tepezza  has been approved for the treatment of active or high clinical activity score (CAS) Thyroid Eye Disease (TED) by Japan’s Ministry of Health, Labour and Welfare (MHLW)…. read more.

Additional data from phase IV Tepezza clinical trial presented at the Endocrine Society annual meeting reinforces efficacy in people with thyroid eye disease (TED) regardless of disease activity or duration – Horizon Therapeutics / Amgen

Written by | 23 Jun 2023

Horizon Therapeutics plc announced the presentation of new data from the randomized, double-masked, placebo-controlled Phase IV clinical trial (NCT04583735) evaluating Tepezza in patients with long disease duration and… read more.

Horizon Therapeutics initiates randomized controlled clinical trial evaluating Tepezza for the treatment of chronic (inactive) thyroid eye disease

Written by | 14 Sep 2021

Horizon Therapeutics plc has announced that the first patient has been enrolled in a Phase IV clinical trial evaluating the efficacy and safety of Tepezza for the treatment… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.